Confirmatory Studies For Rare Diseases Shouldn’t Need To Start Before Accelerated Approval, Stakeholders Argue

 
• By Derrick Gingery
clinical trial use
A blanket mandate to start confirmatory trials when accelerated approval is granted could force significant investment in surrogate endpoints that are not accepted. • Source: Shutterstock

More from Post-Marketing Regulation & Studies

More from Product Reviews